Ralliant Corporation $RAL Shares Sold by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC decreased its holdings in shares of Ralliant Corporation (NYSE:RAL) by 84.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,906 shares of the company’s stock after selling 44,557 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Ralliant were worth $352,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mutual of America Capital Management LLC acquired a new position in Ralliant during the third quarter worth $552,000. Whittier Trust Co. of Nevada Inc. increased its stake in shares of Ralliant by 366.6% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 10,504 shares of the company’s stock worth $465,000 after purchasing an additional 8,253 shares in the last quarter. Westfuller Advisors LLC acquired a new position in shares of Ralliant during the 3rd quarter worth about $26,000. Teacher Retirement System of Texas lifted its stake in Ralliant by 3,000.8% in the 3rd quarter. Teacher Retirement System of Texas now owns 534,078 shares of the company’s stock valued at $23,355,000 after buying an additional 516,854 shares in the last quarter. Finally, Osborne Partners Capital Management LLC acquired a new stake in Ralliant in the 3rd quarter worth about $575,000.

Key Ralliant News

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Analyst upgrades: Vertical Research upgraded Ralliant from “hold” to “buy” with a $45 price target, which supports near‑term upside expectations. The Fly: Vertical Research upgrade
• Positive Sentiment: Citigroup maintained a “buy” rating (but trimmed its PT to $51 from $61), which still implies meaningful upside and likely helped calm some selling pressure. Benzinga: Citigroup note
• Positive Sentiment: Quarterly results modestly beat: Q4 EPS of $0.69 (vs. $0.67 est.) and revenue of ~$554.6M (vs. $543M est.), showing underlying operational resilience despite the one‑time items. MarketBeat: Q4 results
• Neutral Sentiment: Company set 2026 revenue target of $2.1B–$2.2B (roughly in line with consensus), which supports the topline outlook but is tempered by other items below. BusinessWire: FY2026 outlook
• Negative Sentiment: Material non‑cash charge: the company recorded a $1.4B goodwill impairment in its Test & Measurement segment (EA Elektro‑Automatik), producing a large reported net loss and triggering the recent sharp selloff. MarketWatch: $1.4B impairment
• Negative Sentiment: Multiple law‑firm investigations and investor notices (Holzer & Holzer, Johnson Fistel, Block & Leviton) are underway into the impairment and disclosures, adding legal/exec‑risk uncertainty. GlobeNewswire: Investor alerts
• Negative Sentiment: Shares recently hit an all‑time low after the impairment and heavy losses were disclosed, which can pressure sentiment until clarity on write‑ups, integration and legal outcomes emerges. InsiderMonkey: All‑time low coverage

Ralliant Stock Up 2.9%

NYSE RAL opened at $39.50 on Friday. The business’s fifty day simple moving average is $51.52 and its 200-day simple moving average is $46.72. The company has a quick ratio of 1.03, a current ratio of 0.84 and a debt-to-equity ratio of 0.38. The firm has a market cap of $4.46 billion and a PE ratio of 31.10. Ralliant Corporation has a 52 week low of $37.27 and a 52 week high of $57.02.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to analyst estimates of $543.04 million. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, March 9th. Ralliant’s payout ratio is presently 15.75%.

Analyst Ratings Changes

A number of brokerages have commented on RAL. Citigroup reduced their target price on Ralliant from $61.00 to $51.00 and set a “buy” rating for the company in a report on Friday. Royal Bank Of Canada reduced their price objective on Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday. Barclays raised their price objective on Ralliant from $59.00 to $60.00 and gave the company an “overweight” rating in a report on Wednesday, January 7th. Truist Financial reduced their target price on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating for the company in a research report on Friday. Finally, Vertical Research raised shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price target on the stock in a research note on Friday. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $51.30.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.